Plain-English translation of NCT05979961 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether patients with nasopharyngeal cancer benefit from receiving gemcitabine and cisplatin chemotherapy before starting their main treatment. All participants will receive radiation therapy combined with cisplatin chemotherapy, but one group will receive three rounds of the additional chemotherapy first to see if it helps prevent the cancer from returning.
Nasopharyngeal cancer can be hard to treat, and doctors want to know if adding extra chemotherapy before the main treatment helps patients live longer and stay cancer-free. This trial will help clarify whether this extra step is worth the additional side effects for patients at lower risk of their cancer spreading.
If you join this trial, you'll be randomly assigned to one of two groups. One group receives radiation therapy five days a week for seven weeks combined with chemotherapy given every three weeks. The other group receives three rounds of extra chemotherapy first (over nine weeks), then the same radiation and chemotherapy combination. Both treatments involve hospital or clinic visits for chemotherapy infusions and daily radiation appointments, with blood tests and scans throughout to monitor your progress and side effects.
AI-generated summary from trial data · Aug 26, 2026 · Not medical advice
China